AH: Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022
PR: Heidelberg Pharma to Present New Data on its Proprietary ATAC® Technology Platform at the AACR Annual Meeting 2022
PR: Heidelberg Pharma Announces Financial Figures for Fiscal Year 2021 and Provides Business Update
PR: Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117
PR: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
AH: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
AH: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini
PR: Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma
PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021
PR: Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences
PR: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US
PR: Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
PR: Heidelberg Pharma Announces Participation at Various Conferences
PM: Annual General Meeting 2021 of Heidelberg Pharma Approves All Proposed Resolutions
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2021
PR: Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021
PR: Heidelberg Pharma announces financial figures for fiscal year 2020 and provides business update
AH: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini
PR: Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine
AH: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
